Next Article in Journal
Hydroxyapatite-poly(d,l-lactide) Nanografts. Synthesis and Characterization as Bone Cement Additives
Previous Article in Journal
Coumarin Derivatives in Inflammatory Bowel Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 2
10.3390/molecules26020423
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi

by
Leonardo S. Lara
1,
Guilherme C. Lechuga
1,
Caroline dos S. Moreira
2,
Thaís B. Santos
2,
Vitor F. Ferreira
2,
David R. da Rocha
2 and
Mirian C. S. Pereira
1,*
1
Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Av. Brasil 4365 Manguinhos, Rio de Janeiro 21040-900, RJ, Brazil
2
Departamento de Química Orgânica, Instituto de Química, Universidade Federal Fluminense, Rua Outeiro São João Batista, Niterói 24020-141, Rio de Janeiro, Brazil
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(2), 423; https://doi.org/10.3390/molecules26020423
Submission received: 25 September 2020 / Revised: 16 October 2020 / Accepted: 21 October 2020 / Published: 15 January 2021
(This article belongs to the Special Issue Drug Design Against Neglected Tropical Diseases)
Browse Figures
Versions Notes

Abstract

:
Chagas disease (CD) still represents a serious public health problem in Latin America, even after more than 100 years of its discovery. Clinical treatments (nifurtimox and benznidazole) are considered inadequate, especially because of undesirable side effects and low efficacy in the chronic stages of the disease, highlighting the urgency for discovering new effective and safe drugs. A small library of compounds (1a–i and 2a–j) was designed based on the structural optimization of a Hit compound derived from 1,4-naphthoquinones (C2) previously identified. The biological activity, structure-activity relationship (SAR), and the in silico physicochemical profiles of the naphthoquinone derivatives were analyzed. Most modifications resulted in increased trypanocidal activity but some substitutions also increased toxicity. The data reinforce the importance of the chlorine atom in the thiophenol benzene ring for trypanocidal activity, highlighting 1g, which exhibit a drug-likeness profile, as a promising compound against Trypanosoma cruzi. SAR analysis also revealed 1g as cliff generator in the structure-activity similarity map (SAS maps). However, compounds C2 and 1g were unable to reduce parasite load, and did not prevent mouse mortality in T. cruzi acute infection. Phenotypic screening and computational analysis have provided relevant information to advance the optimization and design of new 1,4-naphthoquinone derivatives with a better pharmacological profile.

Graphical Abstract

1. Introduction

Chagas disease (CD), a serious parasitic disease caused by T. cruzi, continues to be a neglected disease with a high social and economic impact in Latin America, despite the control strategies of the World Health Organization’s programs launched to combat this disease [1]. Unlike other neglected tropical diseases (NTDs), little progress has been achieved in the treatment and diagnosis of CD, with the pediatric formulation of benznidazole (Bz) [2], the reference drug, and the recent approval of Bz by the United States Food and Drug Administration [3] being the major advances to date.
Despite improved control of vector-borne transmission in wide areas of Southern Cone countries, outbreaks of oral infection and the appearance of secondary peridomestic vectors have resulted in the re-emergence of acute infection in many endemic countries [4,5,6]. Non-endemic countries have also faced this silent disease because of the emigration of asymptomatic infected individuals, who are unaware that they harbor T. cruzi, making disease control a major challenge for the local public policies and hence, a global public health problem [7].
The limitations of the drugs used in the clinical treatment, Bz and nifurtimox, call attention to the elements possibly involved with the therapeutic failure, including (i) Serious adverse effects, leading to discontinuation of treatment [8]; (ii) the genetic variability of T. cruzi and the presence of naturally resistant strains [9,10]; (iii) the state of dormancy of T. cruzi and its resistance to treatment [11] and the low efficacy of Bz in chronic phase [12]. In this scenario, the search for new therapeutic regimens of reference drugs, aiming to preserve efficacy and minimize the side effects, as well as the identification of new targets, potent and safe drugs are urgently needed for the treatment of CD. Clinical trials have been critical in deepening the knowledge about the efficacy of Bz in the chronic phase and its synergistic action in combined therapy with promising new drugs, as well as in evaluating the efficacy of new or repositioned drugs as control strategies to fight DC. The BENEFIT (Benznidazole Evaluation for Interrupting Trypanosomiasis) trial revealed the progress of chronic chagasic cardiomyopathy even after treatment with Bz [13]; the lack of efficacy of Posaconazole monotherapy and combined therapy with Bz has been demonstrated in the Chagazol [14] and Stop-Chagas [15] clinical trials, respectively. The phase II proof of concept of fexinidazole showed a reduction of the parasitic burden at low doses but the treatment was discontinued because of safety and tolerability [16]. Recently, the benznidazole New Doses Improved Treatment and Associations (BENDITA) trial, which demonstrated low-dose efficacy of Bz in a short-course regimen, offered new hope for treatment with good efficacy and reduced side effects [17], but prevention of cardiomyopathy progression is yet to be evaluated.
Efforts in the design and discovery of new drugs led to the identification of several hit and lead compounds that advanced for optimization in an attempt to achieve more effective trypanocidal drugs [18]. Virtual computational predictions have guided promising candidates to move forward to preclinical in vivo assays [19]. In silico analyses have highlighted multiple physicochemical parameters as a strategy to improve molecules with greater potential to successfully overcome adverse toxicological outcomes [20] and even alert to possible risks that may contribute to compound failure [21]. The analysis of the structure-activity relationship (SAR) has also been exploited in the design of new drugs, providing valuable information about how structural changes can improve potency and bioavailability [22].
Naphthoquinone derivatives, including 2-phenoxy-1,4-naphthoquinone, have been proposed as an attractive anti-trypanosomal phenotypic hit attributable to their multitarget mode of action [23,24]. Naphthoquinones, an important class of natural products of wide biological application, have been reported to inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) intervening in the glycolytic pathway [25], inhibiting tubulin polymerization and exhibiting antiproliferative activity [26], and inducing oxidative stress by generating reactive oxygen species (ROS) [27,28]. In this subject area, we have previously reported the 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivative, compound 2 (C2), as a potential hit compound [29]. C2 showed no cardiotoxic effect and trypanocidal activity against clinically relevant forms of T. cruzi. Thus, a small library of 1,4-naphthoquinone derivatives (19 derivatives) was designed aiming to explore the structural activity relations (SAR) of C2 and optimize its trypanocidal activity. Based on the structure of C2, in which we noted the importance of the chlorine atom in the thiophenol benzene ring, we employed the previously reported anti-T. cruzi activity of para- chlorobenzene group [29] and analyzed the effect generated by both the introduction of more chlorine atoms, and varying their position in the final structure. Knowing that one of the main mechanisms of action of naphthoquinones is related to the generation of ROS [28] and considering our previous findings that demonstrated greater ROS generation by the introduction of a hydroxyl group in the aromatic ring of the naphthoquinones [29], we also evaluated the effect caused by this pattern in C2. Furthermore, the introduction of 4-CH3 and 4-OCH3-phenylgroups considered C2′s ability to potentiate the trypanocidal activity, as described in lapachone-derived naphthoimidazoles and naphthofuranquinones compared to parental compounds [30,31]. The presence of methylthio group (SCH3) has been associated with the redox potential of several naphthoquinones, since these compounds can participate in oxidation reactions forming reactive sulfur species [32]. Other substituents, including fluoro (F), nitro (-NO2), propyl (C3H7), and naphthyl (C10H8) groups were added in order to improve the therapeutic properties.
In this study, a small library of 1,4-naphthoquinone derivatives was synthesized and screened against T. cruzi. Also, a computational multi-parameter analysis was performed to predict physicochemical properties, analyze structure-activity relationship and systematically characterize the activity landscape of 1,4-naphthoquinone derivatives against T. cruzi, allowing us to determine structural changes associated with activity differences, in order to identify a promising candidate for treatment of Chagas disease.

2. Results

2.1. Hit Compound Optimization

The series of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives (1a–f, 1h and 1i) was designed considering the results reported in previous studies of our research group, where we observed that the introduction of chlorine atoms in R1, combined with benzene in R2, promoted good anti-T. cruzi activity [29]. Inspired by these results, we started this study trying to improve the anti-T. cruzi activity by exploring the introduction of electron-withdrawing groups like chlorine in R1 (compounds 1a–d) and/or electron-releasing groups like methoxy (OCH3; 1g–i) in R2. Later, in order to better correlate anti-T. cruzi activity and the electronic profile, we designed a new series of compounds (2a–j) to study the effect of different substituents in R1 (CH3, NO2, F, OCH3, SCH3, C3H7, C10H8) in the presence of methoxy group, an electron-donating group, in the benzene ring (R2) [33]. Finally, we decided to observe if the introduction of a triazole in R2 (1-(3,5-dichlorophenyl)-1H-1,2,3-triazole, 1e), a heterocycle extensively present in antiproliferative compounds [27], or presence of hydroxyl group in the quinonic aromatic ring (R3; 1f), usually associated with increased ROS formation [34], could improve anti-T. cruzi activity.

2.2. In Vitro Biological Evaluation

The small library (1a–i and 2a–j) was analyzed for its toxicity profile in mammalian cells and trypanocidal activity against trypomastigotes and intracellular amastigotes of two different T. cruzi lineages (TcI and TcII). The toxicity levels of the 1,4-naphthoquinone derivatives in Vero cells resulted in CC50 values ranging from 24.4 to 141.8 µM while Bz reached CC50 > 500 μM (Table 1). The compound 1h, consisting of OCH3 in 2 (ortho) and 4 (para) positions of the benzene ring (R2), was the most cytotoxic of the series (CC50 = 24.4 ± 2.6 μM). Most compounds showed high toxicity, with a CC50 in the range of 34–49 μM, except compounds 1d (82.1 ± 5.1 μM), 1g (99.9 ± 12.5 μM), 2d (141.8 ± 17.6 μM), and 2j (93.5 ± 6.6 μM) (Table 1).
Regarding trypanocidal activity, both series were analyzed for effect on Dm28c expressing luciferase (Dm28c-Luc; TcI) and Y strain (TcII) trypomastigotes. Among the 19 derivatives screened, only eight compounds, six of series 1 (1a–e and 1g) and two of series 2 (2f and 2g), showed higher activity than Bz (Y strain − CC50 = 14.3 ± 3.2 μM; Dm28c-Luc − CC50 = 17.5 ± 3.3 μM) for both Y strain and Dm28c-Luc trypomastigotes (Table 1). Although compound 1e was shown to be more effective (IC50 approximately 4.5 μM) against T. cruzi trypomastigotes, it presented a low selectivity index (SI) because of its high cytotoxicity to mammalian cells (CC50 = 34.1 ± 2.9 μM). Only compound 1g (CC50 = 99.9 ± 12.5 μM) presented SI ≥ 9.8 for both T. cruzi stocks, reaching IC50 values of 1.4- to 2-fold lower than the Bz for Y strain (IC50 = 10.2 ± 0.5 μM) and Dm28c-Luc (IC50 = 8.1 ± 0.6 μM), respectively (Table 1). The IC90 reached values ≤ 19.3 μM for trypomastigotes (Y strain and Dm28c clone), showing greater efficacy than Bz (IC90 > 100 μM). The luminescent screening assay for naphthoquinone derivatives (1a–i and 2a–j) targeting intracellular amastigotes (Dm28c-Luc) revealed six most active derivatives (1a, 1b, 1g, 2a, 2e, and 2f) (Table 2). Although these derivatives have IC50 values ≤6.9 µM, they showed lower activity than Bz (IC50 = 1.4 ± 0.4 µM). However, 1g (IC50 = 6.7 ± 1.8 μM) was the only derivative with SI > 10 among the most active compounds (Table 2).

2.3. Computational Analysis: Physicochemical Properties, SAR, and SAS Maps

The high structure similarity and high activity difference between molecules of the series led us to analyze structure-activity relationship (SAR), using the concept of activity landscape, and the physicochemical properties of all derivatives. In this light, structure-activity similarity (SAS) maps were analyzed with emphasis on the activity cliff that clusters structurally similar compound pairs with large activity differences. The SAS maps for the 19 derivatives against trypomastigotes and intracellular amastigotes revealed 172 data points with each one corresponding to a pairwise comparison (Figure 1). Data points were additionally differentiated by the potency (pIC50) using a color scale from low (blue) to high (red). Most of the compound pairs generated for trypomastigotes and intracellular amastigotes were identified in similarity cliff (region III; R3) and smooth SAR (region IV; R4), showing small structural similarity with high activity similarity and high structural and activity similarity, respectively (Figure 1). The quantitative analysis revealed that 86.5% and 77.7% of compound pairs were distributed in the R3 and R4 regions of SAS maps for both amastigotes and trypomastigotes, respectively (Figure 1). In contrast, the compound pairs’ lowest proportion of data points were in the activity cliff (region II; R2). A higher proportion of activity cliff pairs was identified for intracellular amastigotes (7%) compared to trypomastigotes (3.5%) (Figure 1). The pairs 1g_2j, 1g_2c, 1g_2a, 1g_2b, 1h_2j, and 1h_2c illustrate the activity cliffs in the SAS map of trypomastigotes. Data points 1g_2h, 1g_2j, 1h_2j, 1i_2j, 2a_2h, 2a_2j, 2b_2j, 2c_2j, 2d_2j, 2e_2j, 2e_2h, and 2i_2j represent the activity cliffs of intracellular amastigotes (Figure 1). Interesting, two compound pairs, 1g_2j and 1h_2j, were identified in the activity cliffs in the SAS map of both trypomastigotes and intracellular amastigotes. Although small structural changes were evident among these molecules, 1g is among the most active compounds while 2j is the least effective compound in the series.
Thus, we addressed the question of how the structural changes in the series affected the physicochemical properties of the derivatives and resulted in drastic changes in compound activity. Then, we assessed the molecular properties typically analyzed in drug discovery software, including molecular mass (MM), lipophilicity (LogP), number of hydrogen donors (HBDs) and acceptors (HBAs), polar surface area (PSA), rotatable bonds, pIC50 and drug-likeness, using Datawarrior software. These properties are important to determine compound absorption, distribution, metabolism, and excretion (ADME) profile. The series 1(a–i) has the highest MW (418.46–542.82) compared to the series 2(a–j), which achieved maximal of 452.42 (Figure 2). Most of the compounds have high lipophilicity (LogP > 4.27), except for 2f with moderate lipophilicity (LogP = 3.9), but they do not violate Lipinski’s rule of five (Ro5) (Figure 2). Hydrogen bonds, which increase aqueous solubility, also fit the Ro5 with HBD < 5 and HBA < 10. The PSA values, associated with permeability and oral absorption prediction, are distinct between the series. The maximum PSA value reached 134.72 Å2 (2f), and three groups of compounds were identified with PSA values of 79.67 Å2 (1a–d), 88.9 Å2 (1g, 2a–e and 2g–h), and 99.9 to 114.2 Å2 (1e–f, 1h, 2i–j) (Figure 2). The number of rotatable bonds, a parameter involved in the molecule flexibility, was also measured in both series. Four (21%), five (47.4%), and six (31.6%) rotatable bonds were observed (Figure 2). Thus, reduced molecule flexibility (≤10 rotatable bonds) and low PSA (≤140 Å2) point to good oral bioavailability of the compounds.
Two main clusters of compounds share similar physicochemical properties. As expected, because of similarity in chemical structure, compounds 1a–d overlap in the same chemical space, with C2 positioned close to this group. High values of HBA and PSA detached compounds 1e, 1h 1i, 2f, 2i, and 2j from the selective compounds (2d, 1g, and C2) in the chemical space. Data dimension reduction was obtained by principal component analysis (PCA) of six relevant physicochemical properties related to Veber and Lipinski rules. Compounds 2a–e, 2h, 1f, and 1g have a set of similar physicochemical properties and clustered in PCA analysis. Chemical space revealed that the first two PCs account for 75% of variance. HBA account for most (0.54) PC1 impact, followed by PSA (0.51) and rotatable bonds (0.48). HBD had the largest contribution to PC2 (0.24) (Figure 2). Most of modifications in these compound series did not alter significantly the activity against parasite, however the variability of physicochemical properties in the analyzed series by PCA revealed a high influence of hydrogen bond descriptors and PSA, parameters related to compound permeability and polarity, which could impact the activity against intracellular amastigote forms.
The structure-activity relationship (SAR) of both series (1a–i and 2a–j) was also investigated to consider the activity against intracellular amastigotes (Table 2). To probe the impact of chlorine substitutions on the trypanocidal activity, chlorine atoms were incorporated at the ortho (1c), meta (1b), or para (1a) positions of the R2 benzene ring. Compared to C2 activity (IC50 = 9.36 ± 1.9 µM), the addition of chlorine atom to meta (IC50 = 6.9 ± 1.5 µM) and para (IC50 = 6.2 ± 0.9 µM) positions slightly improved the biological activity, while chlorine substitution at ortho position (IC50 = 9.3 ± 0.8 µM) retained the activity of C2, but these analogs have greatly increased cytotoxicity (Table 2). Chlorine atom addition to the ortho position of R1 group (1d) led to less trypanocidal activity (IC50 = 13.5 ± 2.1 µM) but increased cell viability (CC50 = 82.1 ± 5.1 µM). Compound 1e, consisting of 1-(3,5-dichlorophenyl)-1H-1,2,3-triazole substitution in R2 group, did not improve anti-T. cruzi activity (IC50 = 9.1 ± 0.7 µM) and enhanced toxicity (CC50 = 34.1 ± 7.5 µM). Incorporation of OH to R3 group (1f) maintained activity (IC50 = 10.1 ± 1.4 µM) but also reduced cell viability (IC50 = 41.1 ± 2.1 µM). Replacement of chlorine atom by methoxy group in the para position of R2 (1g) improved the activity (IC50 = 6.7 ± 1.8 µM) and toxicity, reaching a selectivity index value of 14.9, and therefore it is highlighted as the most promising compound in the series. However, the introduction of two (1h) or three (1i) methoxy groups in R2 resulted in toxicity (24–34 µM) without benefit to trypanocidal activity. The chlorine atom substitution in R1 of 1g for thiol group (2j) led to the loss of trypanocidal activity, reducing by ten-fold its IC50 value (Table 2). However, the substitution of the thiol group in R1 of 2j by the methoxy group (2i) increased by approximately four-fold the anti-T. cruzi activity (IC50 = 15.8 ± 3.2 µM), but reduced by 50% the cell viability (CC50 = 44.8 ± 3.3 µM). Although the substitution of the chlorine atom of 1g for the fluorine atom at the para position of the R1 benzene ring (2e) resulted in anti-parasitic activity similar to 1g, compound 2e showed higher toxicity (CC50 = 47.7 ± 3.2 µM). Exchanging the chlorine atom in compound 1g by the methyl group at the para position of the benzene ring (2d) reduced compound activity (IC50 = 11.9 ± 1.7 µM) but recovered the cell viability (CC50 = 141.8 ± 17.6 µM). Substitution of the methyl group at the ortho (2b) or meta (2c) position did not alter trypanocidal activity (approximately 12 µM), while its exclusion in compound 2a increased the activity (IC50 = 6.7 ± 1.6 µM), but all these compounds markedly increased toxicity (44–48 µM) compared to 2d (Table 2). The introduction of nitro (NO2) group (2f) to R1 instead of thiol group (2J) increased ten-fold the biological activity, but the impairment to cell viability is highlighted. Differential anti-T. cruzi activity was achieved after addition of propyl (2g; IC50 = 10.3 ± 2.4 µM) and naphthyl (2h; IC50 = 22.4 ± 2.2 µM) substituents in R1 but highly increased (2.3-fold) cytotoxicity (Table 2).

2.4. Trypanocidal Activity in Mouse Model of Acute Infection

Based on the promising in vitro trypanocidal effects of compound C2, previously identified as a hit compound [29], and the trypanocidal activity of 1g, we proceed with these compounds for in vivo assay using a murine model of T. cruzi acute infection. First, we subjected the mice to five cumulative oral (o.p.) and intraperitoneal (i.p.) doses, 1 h apart, at concentrations of 50 mg/kg and 100 mg/kg of compounds C2 and 1g for acute toxicity assessment (NOAEL). No toxic side effects, according to the OECD guidelines, were noted up to 48 h post-treatment at the total cumulative dose of 250 mg/kg for both compounds analyzed (data not shown). Additionally, changes in mouse behavioral characteristics were not observed. However, one animal died in the intraperitoneal treatment regimen of 1g at the cumulative dose of 500 mg/kg.
Next, the efficacy of C2 and 1g was then evaluated in Swiss Webster male mice infected with 104 bloodstream trypomastigotes (Y strain) followed by i.p. treatment with C2 and 1g for 5 consecutive days after detection of positive parasitemia (5 dpi). Untreated and vehicle-only groups had high levels of parasitemia, as expected for this acute model of T. cruzi infection, achieving parasitemia peak at 8 dpi (Figure 3). C2 and 1g treatment was not efficient in eliminating the parasites. The parasitic load of the C2 and 1g treated groups remained similar or even slightly higher than the untreated or vehicle-treated control groups (Figure 3). In contrast, the Bz-treated group had undetectable parasitemia by microscopic analysis. Besides not reducing the parasite burden, the compounds did not bring benefits to the animals survival. Treatment with 1,4-naphthoquinones-derived compounds was not able to prevent mortality, as evidenced by Bz treatment (Figure 3). Most animals, untreated and treated with naphthoquinone derivatives (C2 and 1g) died between 14 and 16 dpi, except for animals treated with 100 mg/kg C2 which died earlier, between 8 and 10 dpi, reaching 100% at the end of treatment (Figure 3). Bz-treated groups survived during all period analyzed (26 days).

3. Discussion

The discovery and development of new drugs is a time-consuming (average 10–15 years) and costly ($800 million to $1 billion) process, which makes it a great challenge for the efficient and safe treatment of various diseases [35]. Despite the increased success rate of molecular entity approval in recent years (2017–2018) [36], only 1.65% of the new products for treatment of neglected tropical diseases (NTDs) entered phase I clinical trial [37]. Among the 20 NTDs proposed for control or elimination by 2020, Chagas disease (CD), discovered 110 years ago, has made little progress in finding new drugs effective in treating the disease. The recently released results of the BENDITA study showed the efficacy of Bz in reduced doses (150 mg/kg) and shorter treatment regimen (2 weeks of treatment) in Bolivian patients [17], produced fewer side effects, bringing new hope for individuals with this silent disease. However, screening for new safe drugs are still a priority, because of natural resistance of T. cruzi strains to reference drug and its inability to prevent cardiomyopathy, encouraging the search for new hit and lead compounds for CD treatment. In this study, we invested in the optimization of a previously identified hit compound (2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone) and analyzed a small library of 1,4-naphthoquinone analogues for their trypanocidal activity using in vitro and in vivo preclinical assays and computational approaches.
Different strategies, based on C-ring, redox center, and A-ring modifications, have been utilized to develop bioactive naphthoquinoidal derivatives with antiplasmodial, trypanocidal, and leishmanicidal activity [38,39]. Herein, we exploited the synthesis of several lapachol analogues containing [1,2,3]-triazole, thiophenol, alkyl, and naphthalene nucleus. Our findings demonstrated that optimization of compound C2, by addition of chlorine atom in the thiophenol benzene ring, increased the lipophilicity (1a–d) improving trypanocidal activity compared to C2 and Bz, and also enhancing mammalian cell toxicity. The high lipophilic character of naphthoquinone derivatives containing furane moiety, methoxy group, and aliphatic side chain has been proposed to benefit the trypanocidal activity by improving the compound permeability through the plasma membrane of the parasite [40]. However, the increased toxicity level has been reported to be related to the promiscuity of highly lipophilic compounds (logP >5) which bind with high affinity to nonspecific hydrophobic targets [41]. Alternatively, the insertion of the heterocyclic ring [1,2,3]-triazole into 1,4-naphthoquinone (1e) enhanced the activity against trypomastigotes, but not amastigotes, compared to Bz. Optimization of 1,4-naphthoquinones activity by the addition of triazole has generated either promising or completely inactive derivatives against T. cruzi [27], suggesting that the position of triazole insertion into quinones or its association with other substitutes modulates its biological activity. High trypanocidal potency has been proposed to be associated with ortho- and para-quinoidal moieties of [1,2,3]-triazole-coupled naphthoquinones and their electrophilic properties, probably related to high ROS induction [42].
Among the 1,4-naphthoquinone derivatives we highlight compound 1g in this small library as a promising compound with a better trypanocidal effect. Although the structural changes were minor, only the inclusion of the methoxy group in the benzene ring of the hit compound (C2) has improved the physicochemical properties, including surface polar area, rotatable bonds and hydrogen bond acceptors, making compound 1g slightly more effective than C2 against trypomastigotes and intracellular amastigotes. It is important to note that merely replacing the chlorine atom with other substituents in series 1(a–i), including halogens and nitro, propyl, naphthyl groups, affecting the physicochemical properties of the derivatives, induced a reduction in trypanocidal activity and increased toxicity.
SAS map indicated the total number of pairwise matches for all compounds, revealed few compounds with similar structures and different activity in activity in the cliff region. Compound 1g, the most active compound evidenced by SAR analysis, was identified as a cliff generator on SAS maps (both trypomastigotes and amastigotes) by pairing with at least five distinct derivatives (2a, 2b, 2c, 2h, and 2j), corroborating the relevance of 4-chlorine in the benzene ring (R1). The change of the chlorine atom in R1 by the 4-methyl (2c), 5-methyl (2b), or thiol group (2j) reduced the trypanocidal activity two- to ten-fold. Comparing with C2, the introduction of the methoxy group to benzene ring in R2 improved the lipophilicity and trypanocidal activity of 1g. In contrast, the other structural changes in R2, by introduction of [1,2,3]-triazole, propyl and naphthyl groups, did not contribute to the improvement of bioactivity. Unfortunately, both compounds C2 and 1g failed to reduce parasite burden or ensure mouse survival, suggesting that physicochemical parameters still need to be improved for better compound bioavailability and effectiveness. Although numerous naphthoquinone derivatives have been analyzed against T. cruzi, few analogues have evolved into preclinical in vivo assays. The 2,3-diphenyl-1,4-naphthoquinone (DPNQ), for instance, has been reported as a potential chemotherapeutic agent against T. cruzi because of its trypanocidal activity in phenotypic screening and in murine T. cruzi experimental infection [43]. Treatment of C3H/HeN female infected mice with DPNQ reduced two-fold the parasite load and ensured 60% animal survival up to 70 dpi, stimulating compound optimization in an attempt to improve efficacy. In fact, the translational interface between in vitro and in vivo assays as well as preclinical and clinical trials is still a major gap in the development of new drugs, demonstrating the importance of physicochemical and pharmacokinetic properties and the choice of experimental models.
In conclusion, the optimization of compound C2, by introduction of methoxy group in benzene ring (1g), moderately improved trypanocidal activity in vitro but highlighted 1g as cliff generator in SAS map. However, C2 and 1g were unable to reduce parasite load, and did not prevent mouse mortality. Design and synthesis of a new library of 1,4-naphthoquinones may contribute to the identification of high potent and low toxic drugs for Chagas disease treatment.

4. Materials and Methods

4.1. Synthetic Compounds

Compounds 1a–i were obtained by multicomponent reaction of lawsone with the appropriate aldehyde to generate the intermediate o-quinone methide in situ, followed by nucleophilic addition of a substituted thiol, as previously described by our group [44].
The reactions were carried out by microwave irradiation (150 °C, 20 min). The results are presented in Figure 4. Naphtoquinones 2a–j were synthetized as previously described [33]. All products were purified by column chromatography using silica gel and were fully characterized by spectroscopic analysis (Supplementary Material).

4.2. General Procedure for Preparing 1a–i and 2a–j

A 10 mL microwave tube was loaded with naphthoquinone (2.9 mmol), aldehyde (5.8 mmol), arylthiol (5.8 mmol), and ethanol (5 mL). The mixture was irradiated for 20 min at 150 °C, and the solvent was then evaporated under reduced pressure. The residual was purified by column chromatography on silica gel and eluted with an increasing polarity gradient of hexane and ethyl acetate.

4.2.1. 2-((4-chlorophenyl)((4-chlorophenyl)thio)methyl)-3-hydroxynaphthalene-1,4-dione (1a)

The reaction produced the compound 1a in 52% as a yellow solid of mp 135–136 °C. IR (KBr, cm−1): ν 3303, 1668, 1641, 1371, 1251, 720. 1H-NMR (CDCl3, 500 MHz) δ (J in Hz): 8.12 (dd, 1H, J = 7.8, 1.0), 8.08 (dd, 1H, J = 7.8, 1.0), 7.78 (td, 1H, J = 7.8, 1.0), 7.70 (td, 1H, J = 7.8, 1.0), 7.68 (s, 1H), 7.58 (d, 2H, J = 8.3), 7.29 (d, 2H, J = 8.3), 7.27 (d, 2H, J = 8.3), 7.21 (d, 2H, J = 8.3), 5.81 (s, 1H) ppm. 13C NMR (CDCl3, 75 MHz): 182.8, 181.3, 152.4, 137.7, 135.5, 134.8, 133.4, 133.3, 133.2, 132.4, 132.3, 129.7, 129.2, 129.1, 128.5, 127.3, 126.4, 122.6, 47.3 ppm. Anal. Calcd. for C23H14Cl2O3S: C, 62.59; H, 3.20; (Exp. C, 62.81; H, 3.19).

4.2.2. 2-((3-chlorophenyl)((4-chlorophenyl)thio)methyl)-3-hydroxynaphthalene-1,4-dione (1b)

The reaction produced the compound 1b in 44% as an orange solid of mp 160–161 °C. IR (KBr, cm−1): ν 3150, 1672, 1634, 1355, 1278, 1237, 731. 1H-NMR (CDCl3, 500 MHz) δ (J in Hz): 8.13 (dd, 1H, J = 7.8, 1.0), 8.08 (dd, 1H, J = 7.8, 1.0), 7.79 (td, 1H, J = 7.8, 1.0), 7.71 (td, 1H, J = 7.8, 1.0), 7.70 (s, 1H), 7.64–7.63 (m, 1H), 7.54–7.52 (m, 1H), 7.31 (d, 2H, J = 8.3), 7.25–7.20 (m, 4H), 5.81 (s, 1H) ppm. 13C NMR (CDCl3, 126 MHz): 182.7, 181.2, 152.4, 141.2, 135.5, 134.7, 134.3, 133.4, 132.4, 132.3, 129.6, 129.2, 129.1, 128.4, 127.6, 127.3, 126.5, 126.4, 122.5, 47.4 ppm. Anal. Calcd. for C23H14Cl2O3S: C, 62.59; H, 3.20; (Exp. C, 62.35; H, 3.21).

4.2.3. 2-((2-chlorophenyl)((4-chlorophenyl)thio)methyl)-3-hydroxynaphthalene-1,4-dione (1c)

The reaction produced the compound 1c in 48% as a yellow solid of mp 183–184 °C. IR (KBr, cm−1): ν 3327, 1670, 1643, 1364, 1280, 723. 1H-NMR (CDCl3, 500 MHz) δ (J in Hz): 8.27 (dd, 1H, J = 7.8, 1.5), 8.13 (dd, 1H, J = 7.8, 1.0), 8.07 (dd, 1H, J = 7.8, 1.0), 7.78 (td, 1H, J = 7.8, 1.0), 7.69 (td, 1H, J = 7.8, 1.0), 7.60 (s, 1H), 7.34 (d, 2H, J = 8.3), 7.32–7.30 (m, 1H), 7.29 (dd, 1H, J = 7.8, 1.5), 7.22–7.20 (m, 3H), 6.21 (s, 1H) ppm. 13C NMR (CDCl3, 75 MHz): 182.5, 181.5, 153.2, 136.0, 135.6, 134.2, 133.7, 133.5, 133.4, 132.8, 132.5, 132.2, 129.5, 129.4, 128.9, 127.5, 126.7, 126.5, 121.4, 45.7 ppm. Anal. Calcd. for C23H14Cl2O3S: C, 62.59; H, 3.20; (Exp. C, 62.76; H, 3.21).

4.2.4. 2-(((2,4-dichlorophenyl)thio)(phenyl)methyl)-3-hydroxynaphthalene-1,4-dione (1d)

The reaction produced the compound 1d in 54% as an orange solid of mp 144–145 °C. IR (KBr, cm−1): ν 3326, 1666, 1647, 1349, 1277, 724. 1H-NMR (CDCl3, 500 MHz) δ (J in Hz): 8.13 (dd, 1H, J = 7.8, 1.0), 8.07 (dd, 1H, J = 7.8, 1.0), 7.78 (td, 1H, J = 7.8, 1.0), 7.71–7.70 (m, 1H), 7.70 (td, 1H, J = 7.8, 1.0), 7.65 (d, 2H, J = 7.3), 7.38 (d, 2H, J = 2.0), 7.31 (dd, 2H, J = 7.3,7.8), 7.24 (d, 2H, J = 8.8), 7.21 (s, 1H), 7.09 (dd, 1H, J = 8.8, 2.0), 5.96 (s, 1H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.5, 152.9, 138.6, 135.6, 135.5, 134.7, 133.5, 133.0, 132.7, 131.7, 129.7, 129.3, 128.7, 128.4, 127.8, 127.7, 127.5, 126.5, 122.6, 46.2 ppm. Anal. Calcd. for C23H14Cl2O3S: C, 62.59; H, 3.20; (Exp. C, 62.56; H, 3.20).

4.2.5. 2-(((4-chlorophenyl)thio)(1-(3,5-dichlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-3-hydroxynaphthalene-1,4-dione (1e)

The reaction produced the compound 1e in 50% as a red solid of mp 142–143 °C. IR (KBr, cm−1): ν 3334, 1673, 1638, 1374, 1258, 740. 1H-NMR (DMSO-D6, 500 MHz) δ (J in Hz): 8.78 (s, 1H), 7.99 (s, 2H), 7.97–7.96 (m, 1H), 7.88–7.87 (m, 1H), 7.76–7.73 (m, 1H), 7.63–7.60 (m, 2H), 7.48 (d, 2H, J = 8.4), 7.31 (d, 2H, J = 8.4), 6.15 (s, 1H) ppm. 13C NMR (DMSO-D6, 126 MHz): 183.3, 181.8, 149.1, 138.2, 135.0, 134.9, 134.4, 133.3, 133.2, 132.5, 131.4, 130.9, 130.4, 130.1, 128.4, 127.4, 125.4, 124.8, 121.9, 118.3, 26.1 ppm. Anal. Calcd. for C25H14Cl3N3O3S: C, 55.32; H, 2.60; N, 7.74; (Exp. C, 55.54; H, 2.61; N, 7.71).

4.2.6. 3-(((4-chlorophenyl)thio)(phenyl)methyl)-2,5-dihydroxynaphthalene-1,4-dione (1f)

The reaction produced the compound 1f in 30% as a red solid of mp 164–166 °C. IR (KBr, cm−1): ν 3335, 1683, 1616, 1324, 1273, 705. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 12.20 (s, 1H), 7.76 (s, 1H), 7.61–7.57 (m, 3H), 7.53–7.48 (m, 1H), 7.29–7.27 (m, 3H), 7.24–7.23 (m, 1H), 7.22–7.15 (m, 4H), 5.80 (s, 1H). ppm. 13C NMR (CDCl3, 75 MHz): 189.1, 180.8, 161.9, 153.1, 139.0, 135.6, 135.2, 133.4, 132.4, 129.4, 129.3, 128.7, 128.4, 127.7, 127.1, 123.0, 119.8, 114.4, 47.5 ppm. Anal. Calcd. for C23H15ClO4S: C, 65.32; H, 3.58; (Exp. C, 65.09; H, 3.59).

4.2.7. 2-(((4-chlorophenyl)thio)(4-methoxyphenyl)methyl)-3-hydroxynaphthalene-1,4-dione (1g)

The reaction produced the compound 1g in 60% as a yellow solid of mp 122–123 °C. IR (KBr, cm−1): ν 3282, 1666, 1648, 1508. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.8, 1.0), 8.06 (dd, 1H, J = 7.3, 1.0), 7.76 (td, 1H, J = 7.3, 1.0), 7.74 (s, 1H), 7.68 (dt, 1H, J = 7.8, 1.0), 7.56 (d, 2H, J = 8.8), 7.30 (d, 2H, J = 8.3), 7.19 (d, 2H, J = 8.8), 6.84 (d, 2H, J = 8.3), 5.84 (s, 1H), 3.77 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.4, 158.8, 152.2, 135.3, 133.2, 132.9, 132.4, 132.0, 131.1, 129.4, 129.1, 129.0, 127.2, 126.2, 123.1, 113.7, 55.2, 47.1 ppm. Anal. Calcd. for C24H17ClO4S: C, 65.98; H, 3.92; (Exp. C, 65.74; H, 3.91).

2.4.8. 2-(((4-chlorophenyl)thio)(2,4-dimethoxyphenyl)methyl)-3-hydroxynaphthalene-1,4-dione (1h)

The reaction produced the compound 1h in 35% as a brown solid of mp 70–71 °C. IR (KBr, cm−1): ν 3331, 1648, 1586, 1258, 1094, 724. 1H-NMR (DMSO-D6, 300 MHz) δ (J in Hz): 8.00–7,96 (m, 3H), 7.83 (td, 2H, J = 7.4, 1.6), 7.78 (dd, 1H, J = 7.4, 1.6), 7.73 (d, 2H, J = 8.4), 6.51 (d, 1H, J = 2.5), 6.48–6.46 (m, 2H), 6.11 (s, 1H), 3.72 (s, 3H), 3.63 (s, 3H) ppm. 13C NMR (DMSO-D6, 75 MHz): 182.3, 180.8, 159.5, 157.2, 154.9, 136.3, 134.5, 132.9, 132.1, 131.6, 130.8, 129.6, 129.1, 128.5, 125.7, 125.4, 123.7, 122.6, 104.6, 98.1, 55.4, 54.9, 40.9 ppm. Anal. Calcd. for C25H19ClO5S: C, 64.31; H, 4.10; (Exp. C, 64.58; H, 4,09).

4.2.9. 2-(((4-chlorophenyl)thio)(2,3,4-trimethoxyphenyl)methyl)-3-hydroxynaphthalene-1,4-dione (1i)

The reaction produced the compound 1i in 30% as a yellow solid of mp 116–117 °C. IR (KBr, cm−1): ν 1671, 1641, 1589, 1289, 1081, 720. 1H-NMR (CDCl3, 500 MHz) δ (J in Hz): 8.13–8.11 (m, 1H), 8.07–8.05 (m, 1H), 7.77–7.74 (m, 2H), 7.72–7.70 (m, 1H), 7.69–7.66 (m, 1H), 7.34 (d, 2H, J = 8.2), 7.19 (d, 2H, J = 8.2), 6.70–6.68 (m, 1H), 6.16 (s, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H) ppm. 13C NMR (DMSO-D6, 126 MHz): 182.4, 180.8, 155.0, 152.4, 150.5, 136.0, 134.5, 133.0, 131.6, 130.9, 130.8, 129.6, 128.6, 125.8, 125.5, 124.6, 122.7, 108.1, 60.2, 55.7, 41.1 ppm. Anal. Calcd. for C26H21ClO6S: C, 62.84; H, 4.26; (Exp. C, 62.79; H, 4.25).

4.2.10. 2-Hydroxy-3-((4-methoxyphenyl)(phenylthio)methyl)naphthalene-1,4-dione (2a)

The reaction produced the compound 2a in 66% as an orange solid of mp 49–51 °C. IR (KBr, cm−1) ν 3338, 1669, 1645, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.12 (dd, 1H, J = 7.7, 1.1), 8.06 (dd, 1H, J = 7.7, 1.1), 7.76 (dt, 1H, J = 7.7, 1.1), 7.72 (s, 1H), 7.68 (dt, 1H, J = 7.7, 1.1), 7.58 (d, 2H, J = 8.8), 7.39–7.37 (m, 2H), 7.22 (t, 2H, J = 7.7), 7.18 (t, 1H, J = 7.7), 6.84 (d, 2H, J = 8.8), 5.91 (s, 1H), 3.78 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 182.9, 181.3, 158.7, 152.3, 136.7, 135.1, 133.0, 132.4, 131.4, 130.4, 129.4, 129.1, 128.8, 127.0, 126.7, 126.1, 123.4, 113.6, 55.1, 46.7 ppm. Anal. Calcd. for C24H18O4S: C, 71.62; H, 4.51; (Exp. C, 71.47; H, 4.52).

4.2.11. 2-Hydroxy-3-((4-methoxyphenyl)(o-tolylthio)methyl) naphthalene-1,4-dione (2b)

The reaction produced the compound 2b in 59% as an orange solid of mp 54–55 °C. IR (KBr, cm−1) ν 3335, 1667, 1509, 1645. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.3, 1.0), 8.06 (dd, 1H, J = 7.8, 1.0), 7.75 (dt, 1H, J = 7.8, 1.0), 7.74 (s, 1H), 7.68 (dt, 1H, J = 7.3, 1.0), 7.58 (d, 2H, J = 8.8), 7.29 (dd, 1H, J = 7.3, 1.0), 7.15 (d, 1H, J = 6.8), 7.10–7.04 (m, 2H), 6.83 (d, 2H, J = 8.8), 5.84 (s, 1H), 3.77 (s, 3H), 2.41 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 181.5, 152.3, 138.7, 135.7, 135.2, 133.1, 132.5, 131.3, 130.7, 130.1, 129.5, 129.1, 127.2, 126.8, 126.5, 126.2, 123.5, 113.7, 55.2, 46.0, 20.6 ppm. Anal. Calcd. for C25H20O4S: C, 72.09; H, 4.84; (Exp. C, 71.98; H, 4.82).

4.2.12. 2-Hydroxy-3-((4-methoxyphenyl)(m-tolylthio)methyl)naphthalene-1,4-dione (2c)

The reaction produced the compound 2c in 65% as a dark red solid of mp 45–47 °C. IR (KBr, cm−1) ν 3346, 1668, 1646, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.7, 1.1), 8.06 (dd, 1H, J = 7.7, 1.1), 7.75 (dt, 1H, J = 7.7, 1.1), 7.76 (s, 1H), 7.67 (dt, 1H, J = 7.7, 1.1), 7.56 (d, 2H, J = 8.8), 7.20 (s, 1H), 7.17 (d, 1H, J = 8.2), 7.11 (t, 1H, J = 7.7), 6.98 (d, 1H, J = 7.7), 6.84 (d, 2H, J = 8.8), 5.90 (s, 1H), 3.77 (s, 3H), 2.26 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.5, 158.7, 152.3, 138.6, 136.4, 135.2, 133.1, 132.5, 131.5, 131.1, 129.4, 129.2, 128.7, 127.7, 127.4, 127.1, 126.2, 123.5, 113.7, 55.2, 46.7, 21.3 ppm. Anal. Calcd. for C25H20O4S: C, 72.09; H, 4.84; (Exp. C, 72.01; H, 4.85).

4.2.13. 2-Hydroxy-3-((4-methoxyphenyl)(p-tolylthio)methyl) naphthalene-1,4-dione (2d)

The reaction produced the compound 2d in 58% as a dark red solid of mp 55–56 °C. IR (KBr, cm−1) ν 3391, 1646, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.10 (dd, 1H, J = 7.6, 1.2), 8.05 (dd, 1H, J = 7.6, 1.2), 7.77–7.72 (m, 2H), 7.67 (dt, 1H, J = 7.6, 1.2), 7.56 (d, 2H, J = 8.8), 7.29 (d, 2H, J = 8.2), 7.03 (d, 2H, J = 8.2), 6.83 (d, 2H, J = 8.8), 5.83 (s, 1H), 3.77 (s, 3H), 2.27 (s, 1H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.5, 158.7, 152.3, 137.1, 135.2, 133.1, 132.8, 132.5, 131.5, 131.4, 129.7, 129.5, 129.2, 127.2, 126.2, 123.6, 113.7, 55.2, 47.5, 21.0 ppm. Anal. Calcd. for C25H20O4S: C, 72.09; H, 4.84; (Exp. C, 71.85; H, 4.84).

4.2.14. 2-(((4-fluorophenyl)thio)(4-methoxyphenyl)methyl)-3-hydroxynaphthalene-1,4-dione (2e)

The reaction produced the compound 2e in 63% as a yellow solid of mp 132–134 °C. IR (KBr, cm−1) ν 3255, 1665, 1649, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.8, 1.0), 8.06 (dd, 1H, J = 7.8, 1.0), 7.76 (dt, 1H, J = 7.3, 1.0), 7.71 (s, 1H), 7.68 (dt, 1H, J = 7.3, 1.0), 7.55 (d, 2H, J = 8.3), 7.39–7.36 (m, 2H), 6.92 (t, 2H, J = 8.8), 6.84 (d, 2H, J = 8.3), 5.77 (s, 1H), 3.77 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.4, 161.5, 158.8, 152.3, 135.2, 133.9, 133.2, 132.5, 131.5, 131.3, 129.5, 129.1, 127.2, 126.2, 123.4, 115.9, 113.7, 55.2, 40.1 ppm. Anal. Calcd. for C24H17FO4S: C, 68.56; H, 4.08; (Exp. C, 68.34; H, 4.09).

4.2.15. 2-Hydroxy-3-((4-methoxyphenyl)((4-nitrophenyl)thio)methyl)naphthalene-1,4-dione (2f)

The reaction produced the compound 2f in 32% as a light brown solid of mp 63–64 °C. IR (KBr, cm−1) ν 3369, 1672, 1645, 1510, 1338. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.14 (dd, 1H, J = 7.9, 0.6), 8.07–8.05 (m, 3H), 7.78 (dt, 1H, J = 7.9, 1.2), 7,70 (dt, 1H, J = 7.9, 0.6), 7.61–7.59 (m, 2H), 7.38–7.36 (m, 2H), 6.86–6.85 (m, 2H),6.09 (s, 1H), 3.77 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 182.9, 181.2, 159.1, 152.5, 147.5, 145.4, 135.5, 133.4, 132.3, 130.0, 129.3, 129.0, 127.2, 126.4, 124.0, 122.1, 114.0, 55.2, 44.6 ppm. Anal. Calcd. for C24H17NO6S: C, 64.42; H, 3.83; N, 3.13; (Exp. C, 64.40; H, 3.84; N, 3.12).

4.2.16. 2-Hydroxy-3-((4-methoxyphenyl)(propylthio)methyl)naphthalene-1,4-dione (2g)

The reaction produced the compound 2g in 51% as a red solid of mp 32–33 °C. IR (KBr, cm-1) ν 3306, 1654, 1640, 1592. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.8, 1.0), 8.06 (dd, 1H, J = 7.8, 1.0), 8.02 (s, 1H), 7.74 (dt, 1H, J = 7.3, 1.0), 7,67 (dt, 1H, J = 7.3, 1.0), 7.54 (d, 2H, J = 8.8), 6.83 (d, 2H, J = 8.8), 5.52 (s, 1H), 3.77 (s, 3H), 2.58–2.54 (m, 2H), 1.65–1.63 (m, 2H), 0.96 (t, 3H, J = 7.3) ppm. 13C NMR (CDCl3, 75 MHz): 183.2, 181.4, 164.4, 158.7, 152.8, 135.6, 133.1, 132.5, 131.5, 129.5, 127.1, 126.1, 123.6, 113.7, 55.5, 43.0, 35.4, 22.7, 13.5 ppm. Anal. Calcd. for C21H20O4S: C, 68.46; H, 5.47; (Exp. C, 68.34; H, 5.49).

4.2.17. 2-Hydroxy-3-((4-methoxyphenyl)(naphthalen-2-ylthio)methyl) naphthalene-1,4-dione (2h)

The reaction produced the compound 2h in 35% as a red solid of mp 56–57 °C. IR (KBr, cm−1) ν 3357, 1669, 1646, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.12 (dd, 1H, J = 7.8, 1.0), 8.05 (dd, 1H, J = 7.3, 1.0), 7.83–7.82 (m, 1H), 7.77–7.73 (m, 3H), 7.72–7.70 (m, 1H), 7.69–7.66 (m, 2H), 7.62 (d, 2H, J = 8.8), 7.48–7.46 (m, 1H), 7.43–7.41 (m, 2H), 6.85 (d, 2H, J = 8.8), 6.04 (s, 1H), 3.77 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.3, 158.7, 152.3, 135.1, 134.2, 133.5, 133.0, 132.4, 132.0, 131.4, 129.5, 129.1, 128.7, 128.4, 128.1, 127.6, 127.3, 127.1, 126.3, 126.1, 125.8, 123.3, 113.7, 55.2, 44.6 ppm. Anal. Calcd. for C28H20O4S: C, 74.32; H, 4.45; (Exp. C, 74.23; H, 4.46).

4.2.18. 2-Hydroxy-3-((4-methoxyphenyl)((4-methoxyphenyl)thio)methyl)naphthalene-1,4-dione (2i)

The reaction produced the compound 2i in 50% as a light brown solid of mp 104–106 °C. IR (KBr, cm-1) ν 3329, 1664, 1649, 1508. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11–8.08 (m, 1H), 8.06 (dd, 1H, J = 7.6, 1.2), 7.77–7.72 (m, 2H), 7.67 (dt, 1H, J = 7.6, 1.2), 7.54 (d, 2H, J = 8.8), 7.35 (d, 2H, J = 8.8), 6.83 (d, 2H, J = 8.8), 6.76 (d, 2H, J = 8.8), 5.72 (s, 1H), 3.77 (s, 3H), 3.75 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.5, 159.4, 158.7, 152.3, 135.1, 134.4, 133.1, 132.5, 131.6, 129.6, 129.2, 127.1, 126.7, 126.1, 123.6, 114.5, 113.6, 55.2, 48.7 ppm. Anal. Calcd. for C25H20O5S: C, 69.43; H, 4.66; (Exp. C, 69.38; H, 4.66).

4.2.19. 2-hydroxy-3-((4-methoxyphenyl)((4-(methylthio)phenyl)thio)methyl)naphthalene-1,4-dione (2j)

The reaction produced the compound 2j in 36% as a dark brown solid of mp 45–47 °C. IR (KBr, cm−1) ν 3350, 1668, 1645, 1509. 1H-NMR (CDCl3, 300 MHz) δ (J in Hz): 8.11 (dd, 1H, J = 7.6, 1.2), 8.06 (dd, 1H, J = 7.6, 1.2), 7.78–7.72 (m, 2H), 7.67 (dt, 1H, J = 7.6, 1.2), 7.56 (d, 2H, J = 8.8), 7.30 (d, 2H, J = 8.2), 7.10 (d, 2H, J = 8.2), 6.83 (d, 2H, J = 8.8), 5.82 (s, 1H), 3.77 (s, 3H), 2.42 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 183.0, 181.4, 158.8, 152.3, 137.8, 135.2, 133.1, 132.8, 132.5, 131.7, 131.4, 129.5, 129.1, 127.2, 126.9, 126.2, 123.4, 113.7, 55.2, 47.5, 15.7 ppm. Anal. Calcd. for C25H20O4S2: C, 66.94; H, 4.49; (Exp. C, 66.68; H, 4.51).

4.3. Cell Culture

Confluent cultures of Vero cells (ATCC® CCL 81™) were dissociated with trypsin-EDTA solution (0.025%) and cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). The cultures were maintained at 37 °C in humidified atmosphere of 5% CO2.

4.4. Parasites

T. cruzi Dm28c-Luc clone, genetically modified to express firefly luciferase, and Y strain were used in the drug screening assay. Vero cells were infected with T. cruzi, Dm28c-Luc or Y strain, in a 10:1 parasites/host cell ratio and maintained at 37 °C in humidified atmosphere of 5% CO2. Trypomastigotes were harvested from the infected culture supernatant on the 4th day post-infection (dpi) followed by quantification of the number of parasites/mL in Neubauer chamber.

4.5. Cytotoxicity In Vitro Assay

To evaluate the toxic effects of the 1,4-naphthoquinone derivatives on mammalian cells, Vero cells were seeded at a density of 1.5 × 104 cells/well in 96-well white culture plates. Twenty-four hours later, the cell cultures were incubated for 72 h at 37 °C with 1,4-naphthoquinone derivatives (series 1(a–i) and 2(a–j)) and Bz (500–1.9 µM) diluted in RPMI medium supplemented with 10% FBS. After incubation, the cell viability, measured by ATP level, was assessed by adding 20 µL/well of the CellTiter Glo (Promega Corporation, Madison, WI, EUA) solution. The luminescent signal was read on the FlexStation 3 reader (Molecular Devices, Sunnyvale, CA, USA). The concentration of compound that reduces 50% of mammalian cell viability (CC50) was determined by linear regression. All treatments and controls were performed at low concentration (≤1%) of dimethyl sulfoxide (DMSO). At least three independent assays were performed in duplicate.

4.6. Trypanocidal Activity

Screening of the compounds was performed against trypomastigotes and intracellular amastigote forms. Trypomastigotes (1 × 106 parasites/well), Dm28c-Luc clone and Y strain, were incubated for 24 h at 37 °C with the 1,4 naphthoquinone derivatives and Bz (0.41–100 μM) and their viability determined by the activity of the luciferase enzyme, after addition of luciferin substrate (300 μg/mL), or CellTiter Glo. The luminescent signal was detected on the FlexStation 3 reader.
The effect of the compounds against intracellular amastigotes was screened in 72 h T. cruzi-infected Vero cells. Briefly, Vero cells seeded (1.5 × 104 cells/well) on 96-well white plate infected with trypomastigotes (Dm28c-Luc) at a 10:1 multiplicity of parasites/cell. After 24 h of infection, the cultures were washed with PBS and then, treated for 72 h at 37 °C with naphthoquinone derivatives and Bz (0.41–100 µM). After treatment, luciferin (300 µg/mL) was added to the culture and the viability of the parasites was assessed by reading the luminescent signal using the FlexStation 3 reader. Controls were also performed in no-toxic concentrations of DMSO (≤1%). The concentration that reduces the number of viable parasites by 50% (IC50) or 90% (IC90) was calculated by linear regression.

4.7. In Silico Analysis

Molecular structure of compounds (SMILES code) and pIC50 (-log IC50) values were inserted in Datawarrior software version 5.0 to explore the chemical space, physicochemical properties, and structure activity-relationship (SAR) [45]. For principal component analysis (PCA), six properties related to Veber and Lipinski rules were applied for each compound. The activity landscape and the structure-activity similarity (SAS) maps were analyzed using Activity Landscape Plotter, an online open web platform (https://www.difacquim.com/d-tools/). MACCS molecular fingerprints were used in SAS map analysis and the threshold for structural similarity were set to 0.8.

4.8. Mouse Acute Toxicity

To establish the no-observed-adverse-effect level (NOAEL), increasing doses of the 1,4 naphthoquinone derivatives were orally (o.p.) and intraperitoneally (i.p.) administered into male Swiss mice (21 to 24 g; n = 2 for each group). Treated animals were separated into two groups: (1) 5 consecutive doses of 50 mg/kg and (2) 100 mg/kg every 1h, totaling a cumulative dose of 250 mg/kg and 500 mg/kg, respectively. Untreated and vehicle treated animals (PBS with 3% Tween-80) were used as control groups. Mice were inspected for toxic and sub-toxic symptoms according to Organization for Economic Co-operation and Development (OECD) guidelines [46].

4.9. In Vivo Experimental T. cruzi Infection

Male Swiss Webster mice (18 g) were obtained from the Institute of Science and Technology in Bio-models of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Mice were housed in groups of 5 animals per cage in a ventilated cabinet under controlled temperature (22 ± 1 °C), 55% ± 5% humidity and a 12 h light-dark light cycle. The animals received water and an ad libitum feeding regimen. Mice were intraperitoneally (i.p.) infected with bloodstream trypomastigotes of T. cruzi Y strain (104 parasites/animal) and parasitemia was daily evaluated from the 4th dpi. Animals were distributed into ten groups: (1) uninfected and untreated, (2) uninfected and treated with C2 (50 mg/kg); (3) uninfected and treated with C2 (100 mg/kg); (4) uninfected and treated with 1g (50 mg/kg), (5) T. cruzi-infected and untreated, (6) T. cruzi-infected and treated i.p. with vehicle, (7) T. cruzi-infected and treated i.p. with C2 50 mg/kg/day, (8) T. cruzi infected and treated i.p. with C2 100 mg/kg/day, (9) T. cruzi-infected and treated i.p. with 1g 50 mg/kg/day, and (10) T. cruzi-infected and treated orally with Bz 100 mg/kg/day. Daily treatment (0.1 mL i.p. dose) started at 5 days post-infection (dpi) with positive parasitemia and followed up to 10 dpi.
Parasitemia was estimated by Pizzy-Brener method [47]. Briefly, animals parasitemia were determined by microscopic quantification of fresh blood (5 µL) collected from animals’ caudal vein. Mortality was daily evaluated up to 26 days and expressed in survival rates. All animal procedures were previously approved by the Oswaldo Cruz Institute Ethical Committee for the Use of Animals (License L15/17).

Supplementary Materials

The following are available online.

Author Contributions

Conceptualization, L.S.L., G.C.L. and M.C.S.P.; methodology, L.S.L., G.C.L., C.d.S.M. V.F.F., T.B.S., D.R.d.R. and M.C.S.P.; software, G.C.L. and L.S.L.; formal analysis, L.S.L., G.C.L. and M.C.S.P.; project administration, M.C.S.P.; funding acquisition, M.C.S.P.; writing—original draft preparation, L.S.L., G.C.L., C.d.S.M., D.R.d.R. and M.C.S.P.; writing—review and editing, L.S.L., G.C.L., C.d.S.M., D.R.d.R. and M.C.S.P.; supervision, D.R.d.R. and M.C.S.P.; All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Oswaldo Cruz Institute of the Oswaldo Cruz Foundation (Fiocruz), Programa Estratégico de Apoio à Pesquisa em Saúde (Papes VI)/Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 421856/2017-3 and 424015/2018-8, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), grant number E-26/010.101050/2018 and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001.

Acknowledgments

The authors thank the Multi-user Research Facility of Bioassay Platform of Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil and Mr. Potter Wickware for editorial oversight.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Not available.

References

  1. World Health Organization. Targets and Milestones for Overcoming Neglected Tropical Diseases 2011–2020. Available online: https://www.who.int/chagas/strategy/en/ (accessed on 7 October 2020).
  2. Drug for Neglected Disease Initiative (DNDi), Paediatric Benznidazole. Available online: https://www.dndi.org/achievements/paediatric-benznidazole/ (accessed on 7 October 2020).
  3. Food and Drug Administration. FDA Approves First U.S. Treatment for Chagas Disease. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-treatment-chagas-disease (accessed on 7 October 2020).
  4. Hernández, C.; Salazar, C.; Brochero, H.; Teherán, A.; Buitrago, L.S.; Vera, M.; Soto, H.; Florez-Rivadeneira, Z.; Ardila, S.; Parra-Henao, G.; et al. Untangling the transmission dynamics of primary and secondary vectors of Trypanosoma cruzi in Colombia: Parasite infection, feeding sources and discrete typing units. Parasit. Vectors 2016, 9, 620–632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Noya, B.A.; Pérez-Chacón, G.; Díaz-Bello, Z.; Dickson, S.; Muñoz-Calderón, A.; Hernández, C.; Pérez, Y.; Mauriello, L.; Moronta, E. Description of an oral Chagas disease outbreak in Venezuela, including a vertically transmitted case. Mem. Inst. Oswaldo Cruz. 2017, 112, 569–571. [Google Scholar] [CrossRef] [PubMed]
  6. Ramírez, J.D.; Montilla, M.; Cucunubá, Z.M.; Floréz, A.C.; Zambrano, P.; Guhl, F. Molecular epidemiology of human oral Chagas disease outbreaks in Colombia. PLoS Negl. Trop. Dis. 2013, 7, e2041. [Google Scholar] [CrossRef] [PubMed]
  7. Carod-Artal, F.J. Policy Implications of the Changing Epidemiology of Chagas Disease and Stroke. Stroke 2013, 44, 2356–2360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Coronel, M.V.; Frutos, L.O.; Muñoz, E.C.; Valle, D.K.; Rojas, D.H. Adverse systemic reaction to benznidazole. Rev. Soc. Bras. Med. Trop. 2017, 50, 145–147. [Google Scholar] [CrossRef] [Green Version]
  9. Zingales, B.; Miles, M.A.; Moraes, C.B.; Luquetti, A.; Guhl, F.; Schijman, A.G.; Ribeiro, I. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem. Inst. Oswaldo Cruz. 2014, 109, 828–833. [Google Scholar] [CrossRef]
  10. Revollo, S.; Oury, B.; Vela, A.; Tibayrenc, M.; Sereno, D. In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV. Pathogens 2019, 8, 197. [Google Scholar] [CrossRef] [Green Version]
  11. Sánchez-Valdéz, F.J.; Padilla, A.; Wang, W.; Orr, D.; Tarleton, R.L. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife 2018, 7, e34039. [Google Scholar] [CrossRef]
  12. Sales Junior, P.A.; Molina, I.; Fonseca Murta, S.M.; Sánchez-Montalvá, A.; Salvador, F.; Corrêa-Oliveira, R.; Carneiro, C.M. Experimental and Clinical Treatment of Chagas Disease: A Review. Am. J. Trop. Med. Hyg. 2017, 97, 1289–1303. [Google Scholar] [CrossRef]
  13. Morillo, C.A.; Marin-Neto, J.A.; Avezum, A.; Sosa-Estani, S.; Rassi Jr, A.; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; et al. BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N. Engl. J. Med. 2015, 373, 1295–1306. [Google Scholar] [CrossRef] [Green Version]
  14. Molina, I.; Gómez, I.; Prat, J.; Salvador, F.; Treviño, B.; Sulleiro, E.; Serre, N.; Pou, D.; Roure, S.; Cabezos, J.; et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N. Engl. J. Med. 2014, 370, 1899–1908. [Google Scholar] [CrossRef] [PubMed]
  15. Morillo, C.A.; Waskin, H.; Sosa-Estani, S.; Del Carmen Bangher, M.; Cuneo, C.; Milesi, R.; Mallagray, M.; Apt, W.; Beloscar, J.; Gascon, J.; et al. STOP-CHAGAS Investigators. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic, T. cruzi Carriers: The STOP-CHAGAS Trial. J. Am. Coll. Cardiol. 2019, 69, 939–947. [Google Scholar] [CrossRef] [PubMed]
  16. Drug for Neglected Disease Initiative (DNDi). Fexinidazole (Chagas). Available online: https://www.dndi.org/diseases-projects/portfolio/fexinidazole-chagas/ (accessed on 7 October 2020).
  17. Drugs for Neglected Diseases Initiative. The Bendita Study: A Phase Ii Study to Assess Safety, Tolerability, and Efficacy of Different Benznidazole Regimens, Alone and in Combination with Fosravuconazole. Available online: https://dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf (accessed on 7 October 2020).
  18. Cerecetto, H.; González, M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals 2010, 3, 810–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Fonseca-Berzal, C.; Arán, V.J.; Escario, J.A.; Gómez-Barrio, A. Experimental models in Chagas disease: A review of the methodologies applied for screening compounds against Trypanosoma cruzi. Parasitol. Res. 2018, 117, 3367–3380. [Google Scholar] [CrossRef]
  20. Meanwell, N.A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 2011, 24, 1420–1456. [Google Scholar] [CrossRef]
  21. Egan, W.J. Predicting ADME properties in drug discovery. In Drug Design: Structure and Ligand-Based Approaches; Merz, K.M., Reynolds, C.H., Eds.; Cambridge University Press: Cambridge, UK, 2010; pp. 165–178. [Google Scholar]
  22. Guha, R. On exploring structure-activity relationship. Methods Mol. Biol. 2013, 993, 81–94. [Google Scholar]
  23. Prati, F.; Bolognesi, M.L. Phenotypic Hits in Anti-Trypanosoma Drug Discovery. Chimica Ricerca. 2014. Available online: https://www.soc.chim.it/sites/default/files/chimind/pdf/2014_5_46_ca.pdf (accessed on 7 October 2020).
  24. Prati, F.; Bergamini, C.; Molina, M.T.; Falchi, F.; Cavalli, A.; Kaiser, M.; Brun, R.; Fato, R.; Bolognesi, M.L. 2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile. J. Med. Chem. 2015, 58, 6422–6434. [Google Scholar] [CrossRef] [Green Version]
  25. Bruno, S.; Uliassi, E.; Zaffagnini, M.; Prati, F.; Bergamini, C.; Amorati, R.; Paredi, G.; Margiotta, M.; Conti, P.; Costi, M.P.; et al. Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule. Chem. Biol. Drug. Des. 2017, 90, 225–235. [Google Scholar] [CrossRef]
  26. Ogindo, C.O.; Khraiwesh, M.H.; George, M., Jr.; Brandy, Y.; Brandy, N.; Gugssa, A.; Ashraf, M.; Abbas, M.; Southerland, W.M.; Lee, C.M.; et al. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorg. Med. Chem. 2016, 24, 3849–3855. [Google Scholar] [CrossRef] [Green Version]
  27. Silva Júnior, E.M.; Jardim, G.A.M.; Menna-Barreto, R.F.S.; de Castro, S.L. Anti-Trypanosoma cruzi compounds: Our contribution for the evaluation and insights on the mode of action of naphthoquinones and derivatives. J. Braz. Chem. Soc. 2014, 25, 1780–1798. [Google Scholar]
  28. Majiene, D.; Kuseliauskyte, J.; Stimbirys, A.; Jekabsone, A. Comparison of the Effect of Native 1,4-Naphthoquinones Plumbagin, Menadione, and Lawsone on Viability, Redox Status, and Mitochondrial Functions of C6 Glioblastoma. Cells Nutr. 2019, 11, 1294–1306. [Google Scholar] [CrossRef] [Green Version]
  29. Lara, L.S.; Moreira, C.S.; Calvet, C.M.; Lechuga, G.C.; Souza, R.S.; Bourguignon, S.C.; Ferreira, V.F.; Rocha Pereira, M.C.S. Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound. Eur. J. Med. Chem. 2018, 144, 572–581. [Google Scholar] [CrossRef] [PubMed]
  30. Menna-Barreto, R.F.; Corrêa, J.R.; Pinto, A.V.; Soares, M.J.; de Castro, S.L. Mitochondrial disruption and DNA fragmentation in Trypanosoma cruzi induced by naphthoimidazoles synthesized from beta-lapachone. Parasitol. Res. 2007, 101, 895–905. [Google Scholar] [CrossRef] [PubMed]
  31. Da Silva, E.M.; de Souza, M.C.B.V.; Fernandes, M.C.; Menna-Barreto, R.F.S.; Pinto, M.D.F.R.; Lopes, F.D.; de Simone, C.A.; Andrade, C.K.Z.; Pinto, A.V.; Ferreira, V.F.; et al. Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones. Bioorg. Med. Chem. 2008, 16, 5030–5038. [Google Scholar] [CrossRef] [PubMed]
  32. Gruhlke, M.C.; Slusarenko, A.J. The biology of reactive sulfur species (RSS). Plant. Physiol. Biochem. 2012, 59, 98–107. [Google Scholar] [CrossRef]
  33. Novais, J.S.; Moreira, C.S.; Silva, A.C.J.A.; Loureiro, R.S.; Sá Figueiredo, A.M.; Ferreira, V.F.; Castro, H.C.; da Rocha, D.R. Antibacterial naphthoquinone derivatives targeting resistant strain Gram-negative bacteria in biofilms. Microb. Pathog. 2018, 118, 105–114. [Google Scholar] [CrossRef] [PubMed]
  34. Da Rocha, D.R.; de Souza, A.C.; Resende, J.A.; Santos, W.C.; dos Santos, E.A.; Pessoa, C.; de Moraes, M.O.; Costa-Lotufo, L.V.; Montenegro, R.C.; Ferreira, V.F. Synthesis of new 9-hydroxy-α- and 7-hydroxy-β-pyran naphthoquinones and cytotoxicity against cancer cell lines. Org. Biomol. Chem. 2011, 9, 4315–4322. [Google Scholar] [CrossRef]
  35. Takebe, T.; Imai, R.; Ono, S. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clin. Transl. Sci. 2018, 11, 597–606. [Google Scholar] [CrossRef]
  36. Khurana, G.; Rohilla, A.; Deep, A. Drug Development Process and Novel Drugs Approved by FDA for 2017–18, Applied Clinical Research. Clin. Trials Regul. Aff. 2018, 5, 80–98. [Google Scholar] [CrossRef] [Green Version]
  37. Jain, N.; Hwang, T.; Franklin, J.M.; Kesselheim, A.S. Association of the Priority Review Voucher with Neglected Tropical Disease Drug and Vaccine Development. JAMA 2017, 318, 388–389. [Google Scholar] [CrossRef]
  38. Brandão, G.C.; Missias, F.C.; Arantes, L.M.; Soares, L.F.; Roy, K.K.; Doerksen, R.J.; Oliveira, A.B.; Pereira, G.R. Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapacho-based compounds. Eur. J. Med. Chem. 2018, 145, 191–205. [Google Scholar]
  39. Da Silva, E.N., Jr.; Jardim, C.; Dhawa, U.; Ackermann, L.; de Castro, S.L. Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones. Eur. J. Med. Chem. 2019, 179, 863–915. [Google Scholar] [CrossRef]
  40. De Castro, S.L.; Batista, D.G.; Batista, M.M.; Batista, W.; Daliry, A.; de Souza, E.M.; Menna-Barreto, R.F.; Oliveira, G.M.; Salomão, K.; Silva, C.F.; et al. Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones. Mol. Biol. Int. 2011, 2011, 306928. [Google Scholar] [CrossRef] [Green Version]
  41. Gao, Y.; Gesenberg, C.; Zheng, W. Oral Formulations for Preclinical Studies: Principle, Design, and Development Considerations. In Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, 2nd ed.; Qiu, Y., Chen, Y., Zhang, G., Yu, L., Mantri, V.R., Eds.; Academic Press: Cambridge, MA, USA, 2017; pp. 455–495. [Google Scholar]
  42. Diogo, E.B.; Dias, G.G.; Rodrigues, B.L.; Guimarães, T.T.; Valença, W.O.; Camara, C.A.; de Oliveira, R.N.; da Silva, M.G.; Ferreira, V.F.; de Paiva, Y.G.; et al. Synthesis and anti-Trypanosoma cruzi activity of naphthoquinone-containing triazoles: Electrochemical studies on the effects of the quinoidal moiety. Bioorg. Med. Chem. 2013, 21, 6337–6348. [Google Scholar] [CrossRef] [Green Version]
  43. Ramos, E.I.; Garza, K.M.; Krauth-Siegel, R.L.; Bader, J.; Martinez, L.E.; Maldonado, R.A. 2,3-diphenyl-1,4-naphthoquinone: A potential chemotherapeutic agent against Trypanosoma cruzi. J. Parasitol. 2009, 95, 461–466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Sharma, A.; Santos, I.; Gaur, P.; Ferreira, V.; Garcia, C.; Rocha, D. Addition of thiols to o-quinone methide: New 2-hydroxy-3-phenylsulfanylmethyl [1,4]-naphthoquinones and their activity against the human malaria parasite Plasmodium falciparum (3D7). Eur. J. Med. Chem. 2013, 59, 48–53. [Google Scholar] [CrossRef]
  45. Sander, T.; Freyss, J.; von Korff, M.; Rufener, C. DataWarrior: An open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. 2015, 55, 460–473. [Google Scholar] [CrossRef]
  46. Organisation for Economic Co-operation and Development (OECD) Guidelines for the Testing of Chemicals. Available online: https://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en (accessed on 7 October 2020).
  47. Brener, Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. 1962, 4, 389–396. [Google Scholar]
Molecules 26 00423 g001 550
Figure 1. Structure-activity similarity maps (SAS maps) for T. cruzi based on chemical structure and biological activity. SAS maps against trypomastigote (A) and intracellular amastigote (B) forms of T. cruzi. Each point represents a pairwise comparison of 1,4-naphthoquinones derivatives. The points are colored to pIC50 values using a continuous scale from low (blue) to high (red) power. R1 = not descriptive; R2 = similar structure and different activity (Cliff activity); R3 = Different structure and similar activity (Similarity cliff) and R4 = Similar structure and activity (Smooth SAR).
Figure 1. Structure-activity similarity maps (SAS maps) for T. cruzi based on chemical structure and biological activity. SAS maps against trypomastigote (A) and intracellular amastigote (B) forms of T. cruzi. Each point represents a pairwise comparison of 1,4-naphthoquinones derivatives. The points are colored to pIC50 values using a continuous scale from low (blue) to high (red) power. R1 = not descriptive; R2 = similar structure and different activity (Cliff activity); R3 = Different structure and similar activity (Similarity cliff) and R4 = Similar structure and activity (Smooth SAR).
Molecules 26 00423 g001
Molecules 26 00423 g002 550
Figure 2. Physicochemical properties of 1,4-naphthoquinone series. Relationship of physicochemical properties between cLogP x Molecular Weight x Drug-likeness × number of aromatic rings (A); polar surface area x hydrogen bond acceptors x hydrogen bond donors x rotatable bonds (B,C) principal component analysis (PCA).
Figure 2. Physicochemical properties of 1,4-naphthoquinone series. Relationship of physicochemical properties between cLogP x Molecular Weight x Drug-likeness × number of aromatic rings (A); polar surface area x hydrogen bond acceptors x hydrogen bond donors x rotatable bonds (B,C) principal component analysis (PCA).
Molecules 26 00423 g002
Molecules 26 00423 g003 550
Figure 3. Effect of 1,4-naphthoquinone derivatives (C2 and 1g) in acute murine model of T. cruzi infection. Parasitemia levels (A) and survival rate (B) of mice intraperitoneally infected with T. cruzi trypomastigote forms (Y strain) and submitted to different treatment regimens (n = 5 animals/group).
Figure 3. Effect of 1,4-naphthoquinone derivatives (C2 and 1g) in acute murine model of T. cruzi infection. Parasitemia levels (A) and survival rate (B) of mice intraperitoneally infected with T. cruzi trypomastigote forms (Y strain) and submitted to different treatment regimens (n = 5 animals/group).
Molecules 26 00423 g003
Molecules 26 00423 g004 550
Figure 4. Structure and yields of 2-hydroxy-3-phenylsulfanylmethyl-[1-4]-naphthoquinone derivates.
Figure 4. Structure and yields of 2-hydroxy-3-phenylsulfanylmethyl-[1-4]-naphthoquinone derivates.
Molecules 26 00423 g004
Table
Table 1. Cytotoxicity and trypanocidal effect of 1,4-naphthoquinone derivatives against trypomastigote forms of T. cruzi.
Table 1. Cytotoxicity and trypanocidal effect of 1,4-naphthoquinone derivatives against trypomastigote forms of T. cruzi.
CompoundsTrypanocidal Effect IC50Trypomastigotes
(Mean ± SD μM)		Vero Cells Toxicity CC50 (Mean ± SD μM)SI * Trypomastigotes
Dm28c-LucY StrainDm28c-LucY
IC50IC90IC50IC90
1a8.9 ± 0.625.1 ± 1.63.1 ± 0.65.8 ± 0.943.6 ± 2.34.815.0
1b9.8 ± 0.530.8 ± 2.93.6 ± 1.68.1 ± 1.342.1 ± 1.94.211.7
1c8.6 ± 1.429.6 ± 5.44.3 ± 3.27.3 ± 2.244.1 ± 2.3 5.110.2
1d9.3 ± 1.123.3 ± 2.12.8 ± 0.65.8 ± 1.182.1 ± 5.18.929.3
1e4.5 ± 0.816.5 ± 2.84.7 ± 1.95.5 ± 0.934.1 ± 2.97.57.2
1f9.8 ± 0.728.1 ± 1.722.3 ± 0.310.9 ± 2.141.1 ± 2.14.21.8
1g8.1 ± 0.619.3 ± 3.410.2 ± 0.516.8 ± 2.599.9 ± 12.512.39.8
1h15.4 ± 4.615.4 ± 4.622.9 ± 7.131.9 ± 6.124.4 ± 2.61.51.1
1i21.5 ± 2.921.5 ± 2.930.1 ± 2.338.9 ± 4.334.2 ± 3.41.61.1
2a27.4 ± 2.932.1 ± 1.631.2 ± 4.338.9 ± 5.345.1 ± 1.91.61.4
2b25.9 ± 2.231.8 ± 0.927.9 ± 4.137.9 ± 6.144.4 ± 3.41.71.5
2c52.3 ± 6.484.6 ± 11.426.2 ± 4.832.8 ± 5.148.9 ± 4.70.91.8
2d24.3 ± 3.482.2 ± 7.731.1 ± 1.849.7 ± 7.1141.8 ± 17.65.44.5
2e24.4 ± 4.431.4 ± 4.420.3 ± 4.132.3 ± 5.147.7 ± 3.21.92.3
2f6.5 ± 3.111.5 ± 3.112.5 ± 1.619.9 ± 3.640.6 ± 2.96.23.2
2g13.7 ± 4.128.7 ± 5.112.7 ± 3.923.7 ± 4.147.7 ± 5.23.53.7
2h21.7 ± 4.739.7 ± 5.724.5 ± 3.634.5 ± 4.663.4 ± 7.12.92.5
2i24.1 ± 2.744.9 ± 6.710.6 ± 0.431.6 ± 5.444.8 ± 3.31.84.2
2j52.7 ± 12.6>10089.6 ± 5.4>10093.5 ± 6.61.71.1
C2#21.3 ± 1.931.6 ± 0.410.1 ± 1.027.8 ± 4.6178.9 ± 6.28.417.6
Bz17.5 ± 3.3>10014.3 ± 3.2>100>500>28.6>34.9
Mean values of three independent experiments ± standard deviations; IC50 and IC90: concentration producing 50% and 90% inhibitory effect on T. cruzi trypomastigote forms, respectively; CC50: concentration that reduces 50% of Vero cell viability. * SI = CC50 Vero cells/IC50 trypomastigote forms of T. cruzi. C2—Hit compound (# data from Lara et al., 2018 [29]).
Table
Table 2. Trypanocidal activity and structure activity relationship (SAR) of 1,4- naphthoquinone derivatives. The effect of changes in R-groups against intracellular amastigotes of T. cruzi (Dm28c-Luc clone).
Table 2. Trypanocidal activity and structure activity relationship (SAR) of 1,4- naphthoquinone derivatives. The effect of changes in R-groups against intracellular amastigotes of T. cruzi (Dm28c-Luc clone).
Molecules 26 00423 i001
CompoundsR1R2R3IC50 Ama (µM)IC90 Ama (µM)CC50 Vero (µM)SI
1a Molecules 26 00423 i002 Molecules 26 00423 i003-6.2 ± 0.912.1 ± 1.343.6 ± 2.37.0
1b Molecules 26 00423 i004 Molecules 26 00423 i005-6.9 ± 1.512.7 ± 1.842.1 ± 1.96.1
1c Molecules 26 00423 i006 Molecules 26 00423 i007-9.3 ± 0.823.1 ± 3.344.1 ± 2.34.7
1d Molecules 26 00423 i008 Molecules 26 00423 i009-13.5 ± 2.131.1 ± 3.182.1 ± 5.16.2
1e Molecules 26 00423 i010 Molecules 26 00423 i011-9.1 ± 0.727.9 ± 3.934.1 ± 7.53.7
1f Molecules 26 00423 i012 Molecules 26 00423 i013 Molecules 26 00423 i01410.1 ± 1.429.1 ± 2.141.1 ± 2.14.1
1g Molecules 26 00423 i015 Molecules 26 00423 i016-6.7 ± 1.811.4 ± 2.199.5 ± 12.514.9
1h Molecules 26 00423 i017 Molecules 26 00423 i018-12.1 ± 3.919.4 ± 3.624.4 ± 2.62.0
1i Molecules 26 00423 i019 Molecules 26 00423 i020-15.9 ± 3.127.2 ± 3.434.2 ± 3.42.1
2a Molecules 26 00423 i021 Molecules 26 00423 i022-6.7 ± 1.625.3 ± 1.945.1 ± 1.96.7
2b Molecules 26 00423 i023 Molecules 26 00423 i024-11.3 ± 1.127.4 ± 2.444.4 ± 3.43.9
2c Molecules 26 00423 i025 Molecules 26 00423 i026-12.6 ± 2.430.9 ± 4.748.9 ± 4.73.8
2d Molecules 26 00423 i027 Molecules 26 00423 i028-11.9 ± 1.728.8 ± 4.6141.8 ± 17.611.9
2e Molecules 26 00423 i029 Molecules 26 00423 i030-6.8 ± 1.519.7 ± 3.247.7 ± 3.27.0
2f Molecules 26 00423 i031 Molecules 26 00423 i032-5.7 ± 1.476.6 ± 4.940.6 ± 2.97.1
2g Molecules 26 00423 i033 Molecules 26 00423 i034-10.3 ± 2.437.7 ± 4.147.7 ± 5.24.6
2h Molecules 26 00423 i035 Molecules 26 00423 i036-22.4 ± 2.231.5 ± 6.163.4 ± 7.12.8
2i Molecules 26 00423 i037 Molecules 26 00423 i038-15.8 ± 3.234.8 ± 5.344.8 ± 3.32.8
2j Molecules 26 00423 i039 Molecules 26 00423 i040-60.2 ± 9.8>10093.5 ± 6.61.5
Bz---1.4 ± 0.47.9 ± 1.2>500>357
C2 * Molecules 26 00423 i041 Molecules 26 00423 i042-9.36 ± 1.9022.6 ± 0.6178.90 ± 6.1819.1
Vero cells infected with T. cruzi, Dm28c-Luc clone (expressing luciferase gene), and treated for 72 h with naphthoquinones derivatives. The data represent the mean and standard deviation of three independent experiments. IC50: concentration producing 50% inhibitory effect of intracellular amastigote forms. CC50: concentration that reduces 50% of Vero cell viability. * SI = CC50 Vero cells/IC50 of amastigote forms of T. cruzi. C2—Hit compound (* data from Lara et al. 2018 [29]).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lara, L.S.; Lechuga, G.C.; Moreira, C.d.S.; Santos, T.B.; Ferreira, V.F.; da Rocha, D.R.; Pereira, M.C.S. Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi. Molecules 2021, 26, 423. https://doi.org/10.3390/molecules26020423

AMA Style

Lara LS, Lechuga GC, Moreira CdS, Santos TB, Ferreira VF, da Rocha DR, Pereira MCS. Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi. Molecules. 2021; 26(2):423. https://doi.org/10.3390/molecules26020423

Chicago/Turabian Style

Lara, Leonardo S., Guilherme C. Lechuga, Caroline dos S. Moreira, Thaís B. Santos, Vitor F. Ferreira, David R. da Rocha, and Mirian C. S. Pereira. 2021. "Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi" Molecules 26, no. 2: 423. https://doi.org/10.3390/molecules26020423

APA Style

Lara, L. S., Lechuga, G. C., Moreira, C. d. S., Santos, T. B., Ferreira, V. F., da Rocha, D. R., & Pereira, M. C. S. (2021). Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against Trypanosoma cruzi. Molecules, 26(2), 423. https://doi.org/10.3390/molecules26020423

Article Metrics

Back to TopTop